FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005087304> ?p ?o ?g. }

• W2005087304 endingPage "521" @default.
• W2005087304 startingPage "515" @default.
• W2005087304 abstract "To investigate the effects of repeated glycyrrhizin ingestion on the oral pharmacokinetics of talinolol, a probe drug for P-glycoprotein (P-gp) activity in humans.Fourteen healthy adult male subjects were enrolled in a two-phase randomized crossover-design study. In each phase the volunteers received placebo or compound glycyrrhizin tablets (75 mg glycyrrhizin three times daily) for 6 days. On the seventh day, a single oral dose of 100 mg talinolol was administered, and blood samples were obtained to determine plasma talinolol concentrations, measured in plasma by high-performance liquid chromatography with an ultraviolet detector. Non-compartmental analysis was used to characterize talinolol plasma concentration-time profiles. All pharmacokinetics parameters were calculated using DAS ver. 2.1 software, and statistical analyses were performed with SPSS ver. 13.0 software. Analysis of variance was used to check the difference of the means of the pharmacokinetic parameters between the two treatments at a significance level of 0.05.All treatments were well tolerated during the study period. The geometric mean ± standard deviation of the AUC(0-∞) for talinolol treated by glycyrrhizin and talinolol treated by placebo was 2,218.3 ± 724.3 and 1,988.2 ± 649.2 ng·h/mL, respectively. The 90 % confidence intervals for the ratio of adjusted geometric means (glycyrrhizin:placebo) for AUC(0-∞) and C (max) fell wholly within the interval [80, 125]. Six days of glycyrrhizin treatment resulted in no significant alterations in the pharmacokinetic parameters (AUC(0-∞), AUC(0-24), C (max), t (max), t (½)) for talinolol.Continuous glycyrrhizin administration had no induction effect on the expression of P-gp in our trial. Further research is needed to study the direct inhibition effect of glycyrrhizin on the function of P-gp with the simultaneous administration of both glycyrrhizin and P-gp substrate." @default.
• W2005087304 created "2016-06-24" @default.
• W2005087304 creator A5028556227 @default.
• W2005087304 creator A5032003297 @default.
• W2005087304 creator A5056966724 @default.
• W2005087304 creator A5061357374 @default.
• W2005087304 creator A5062187564 @default.
• W2005087304 creator A5064832836 @default.
• W2005087304 creator A5065598852 @default.
• W2005087304 creator A5069511766 @default.
• W2005087304 date "2012-09-15" @default.
• W2005087304 modified "2023-09-24" @default.
• W2005087304 title "Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers" @default.
• W2005087304 cites W1968966910 @default.
• W2005087304 cites W1971996032 @default.
• W2005087304 cites W1981178961 @default.
• W2005087304 cites W1983534893 @default.
• W2005087304 cites W1989316813 @default.
• W2005087304 cites W2005375909 @default.
• W2005087304 cites W2008077991 @default.
• W2005087304 cites W2015098698 @default.
• W2005087304 cites W2017496976 @default.
• W2005087304 cites W2023731023 @default.
• W2005087304 cites W2037989279 @default.
• W2005087304 cites W2040879255 @default.
• W2005087304 cites W2046877654 @default.
• W2005087304 cites W2047384307 @default.
• W2005087304 cites W2054458932 @default.
• W2005087304 cites W2055645153 @default.
• W2005087304 cites W2061369376 @default.
• W2005087304 cites W2065076492 @default.
• W2005087304 cites W2078198822 @default.
• W2005087304 cites W2100846606 @default.
• W2005087304 cites W2105037592 @default.
• W2005087304 cites W2117927958 @default.
• W2005087304 cites W2123467745 @default.
• W2005087304 cites W2132001275 @default.
• W2005087304 cites W61975853 @default.
• W2005087304 doi "https://doi.org/10.1007/s00228-012-1391-6" @default.
• W2005087304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22983284" @default.
• W2005087304 hasPublicationYear "2012" @default.
• W2005087304 type Work @default.
• W2005087304 sameAs 2005087304 @default.
• W2005087304 citedByCount "12" @default.
• W2005087304 countsByYear W20050873042015 @default.
• W2005087304 countsByYear W20050873042016 @default.
• W2005087304 countsByYear W20050873042017 @default.
• W2005087304 countsByYear W20050873042019 @default.
• W2005087304 countsByYear W20050873042020 @default.
• W2005087304 countsByYear W20050873042021 @default.
• W2005087304 countsByYear W20050873042022 @default.
• W2005087304 crossrefType "journal-article" @default.
• W2005087304 hasAuthorship W2005087304A5028556227 @default.
• W2005087304 hasAuthorship W2005087304A5032003297 @default.
• W2005087304 hasAuthorship W2005087304A5056966724 @default.
• W2005087304 hasAuthorship W2005087304A5061357374 @default.
• W2005087304 hasAuthorship W2005087304A5062187564 @default.
• W2005087304 hasAuthorship W2005087304A5064832836 @default.
• W2005087304 hasAuthorship W2005087304A5065598852 @default.
• W2005087304 hasAuthorship W2005087304A5069511766 @default.
• W2005087304 hasBestOaLocation W20050873041 @default.
• W2005087304 hasConcept C112705442 @default.
• W2005087304 hasConcept C142724271 @default.
• W2005087304 hasConcept C185592680 @default.
• W2005087304 hasConcept C204787440 @default.
• W2005087304 hasConcept C27081682 @default.
• W2005087304 hasConcept C2776332754 @default.
• W2005087304 hasConcept C2777056448 @default.
• W2005087304 hasConcept C42404028 @default.
• W2005087304 hasConcept C43617362 @default.
• W2005087304 hasConcept C71924100 @default.
• W2005087304 hasConcept C87813604 @default.
• W2005087304 hasConcept C98274493 @default.
• W2005087304 hasConceptScore W2005087304C112705442 @default.
• W2005087304 hasConceptScore W2005087304C142724271 @default.
• W2005087304 hasConceptScore W2005087304C185592680 @default.
• W2005087304 hasConceptScore W2005087304C204787440 @default.
• W2005087304 hasConceptScore W2005087304C27081682 @default.
• W2005087304 hasConceptScore W2005087304C2776332754 @default.
• W2005087304 hasConceptScore W2005087304C2777056448 @default.
• W2005087304 hasConceptScore W2005087304C42404028 @default.
• W2005087304 hasConceptScore W2005087304C43617362 @default.
• W2005087304 hasConceptScore W2005087304C71924100 @default.
• W2005087304 hasConceptScore W2005087304C87813604 @default.
• W2005087304 hasConceptScore W2005087304C98274493 @default.
• W2005087304 hasIssue "3" @default.
• W2005087304 hasLocation W20050873041 @default.
• W2005087304 hasLocation W20050873042 @default.
• W2005087304 hasOpenAccess W2005087304 @default.
• W2005087304 hasPrimaryLocation W20050873041 @default.
• W2005087304 hasRelatedWork W1978059029 @default.
• W2005087304 hasRelatedWork W1984317973 @default.
• W2005087304 hasRelatedWork W2005087304 @default.
• W2005087304 hasRelatedWork W2018313535 @default.
• W2005087304 hasRelatedWork W2055974197 @default.
• W2005087304 hasRelatedWork W2056422086 @default.
• W2005087304 hasRelatedWork W2349338867 @default.
• W2005087304 hasRelatedWork W2385472588 @default.

• next